Agenda | MedTech World Europe

Capital is no longer chasing promise alone. This panel brings together venture, growth equity, strategic, and cross-border investors to examine how the bar for MedTech investment has fundamentally shifted, what it now takes to attract and retain capital at every stage, and where the next wave of opportunity lies.

Every MedTech founder faces a defining moment: push forward independently, bring in a strategic partner, or crystallise value through an exit. This panel unpacks the real decisions behind the headline moves, exploring timing, leverage, valuation, and what founders wish they had known before sitting across the table from investors.

Clinical evidence is no longer just a regulatory checkbox. This panel explores how MedTech companies can align their evidence generation strategy with the expectations of investors, payers, and hospital procurement teams, turning regulatory milestones and real-world data into commercial momentum and long-term strategic value.

Every product decision, partnership, and market entry choice sends a signal to potential acquirers and long-term investors alike. This panel examines how MedTech leaders can build companies that are strategically valuable on their own terms, whether the end goal is an exit, a partnership, or independent scale.

Cardiovascular MedTech is experiencing one of its most dynamic periods in a generation. From pulsed field ablation to structural heart innovation, advanced imaging and robotic assisted procedures, this panel examines which technologies are proving their clinical and commercial case, and where the next wave of investment and adoption is heading.

A compelling pitch is not just a slide deck. This session brings together investors and founders to break down what separates a story that converts from one that falls flat, covering narrative structure, credibility signals, common mistakes, and how to communicate vision without losing sight of commercial reality.

Longevity has graduated from wellness trend to serious investment category. This panel examines how the science of ageing is attracting institutional capital, what separates credible clinical programs from consumer noise, and how MedTech and HealthTech companies can position themselves at the intersection of prevention, diagnostics, and lifespan extension.

Non-dilutive capital can be a founder’s most powerful and most misunderstood tool. This panel brings together founders and funding experts to demystify grant strategy, government programs, and innovation schemes, sharing what actually works, what wastes time, and how to combine non-dilutive funding with equity raises effectively.

Durable medical equipment and supply chain operations face mounting pressure from reimbursement constraints, procurement complexity, and margin erosion. This panel examines how companies navigating DME and supply chain challenges can build sustainable models, align with payer expectations, and turn reimbursement strategy into a genuine competitive advantage rather than an afterthought.

Women remain underrepresented in clinical trials and underserved by device design. This panel moves beyond the FemTech label to examine the systemic research gaps in cardiology, oncology, and neurology, exploring how sex-disaggregated data, inclusive trial design, and purpose-built devices can close the gap and unlock a significantly underaddressed market

After Approval: Keeping MedTech Products Compliant, Competitive and on the Market Regulatory approval is the beginning, not the finish line. This panel examines the post-market responsibilities that determine long-term commercial viability, from vigilance and real-world performance monitoring to cybersecurity, supplier changes, and recalls, exploring how companies can meet evolving regulatory expectations without disrupting supply or stalling product development.

Oncology MedTech is advancing on multiple fronts simultaneously. This panel explores the clinical and commercial trajectory of liquid biopsy, AI powered imaging, and surgical navigation, examining where the evidence is strongest, where capital is flowing, and which innovations are closest to reshaping how cancer is detected, staged, and treated.

Primary care is under pressure and technology has a role to play. This panel explores how MedTech and HealthTech companies are embedding innovation at the point of first contact, improving early detection, chronic disease management, and care coordination, and what it takes to build viable commercial models in primary care settings.

Exits rarely happen by accident. This panel brings together investment bankers and exited founders to examine what actually drives MedTech deals, how companies position themselves for acquisition, what strategics are actively looking for right now, and the missteps that have caused otherwise strong businesses to lose value at the finish line.

Neurotech has moved from scientific curiosity to serious investment thesis. This panel explores why leading investors are committing capital to brain computer interfaces, neurostimulation, and neurological diagnostics, what clinical and commercial milestones are required to justify the risk, and where the field is heading next.

Hospital networks are no longer passive adopters of innovation. This panel pulls back the curtain on how health system venture arms evaluate, back, and scale MedTech companies from within, exploring their investment criteria, the tension between clinical mission and financial return, and how founders can best engage them.

Regulatory strategy is no longer a back-office function. This panel examines how MedTech companies can build regulatory capability that accelerates market access across the US, Europe, and Asia, turning compliance into a competitive advantage and avoiding the costly missteps that stall otherwise promising technologies.

Hospital procurement has never been harder. This panel explores how MedTech commercial teams can navigate budget constraints, extended sales cycles, and committee driven decisions, making the case for adoption through health economics, outcomes data, and partnerships that align with what health systems actually need right now.

Software and deep tech investors are increasingly entering MedTech, bringing different assumptions about speed, scalability, and returns. This panel examines what happens when technology capital meets the realities of clinical validation and regulatory timelines, and how MedTech founders can bridge the gap between two very different investment cultures.

The diagnostics landscape is being redrawn by continuous, connected, and consumer facing technologies. This panel examines how wearables and biosensors are shifting care from episodic to real time, what it takes to generate reimbursable clinical evidence, and where investors and health systems are placing their bets in 2026.

Malta as a Life Sciences Gateway: Regulatory Advantage, FDI & the Case for Setting Up Here Malta offers a compelling combination of EU regulatory access, established life sciences infrastructure, and a business environment designed to attract foreign investment. This panel makes the case for Malta as a serious base for MedTech and life sciences companies looking to enter or expand across Europe, with practical insight from those who have already made the move.

The surgical robotics race is entering a new phase. Beyond the pioneers, a new generation of platforms is competing on cost, versatility, and outcomes data. This panel examines who has the technology, capital, and clinical partnerships to define the next decade of robotic assisted surgery.

Healthcare is moving beyond AI pilots toward automation that is embedded in clinical reality. This panel examines how agentic and ambient AI can reduce administrative burden across documentation, coding, scheduling, and research, what it takes to move from experimentation to routine clinical use, and how MedTech companies can build these capabilities directly into their products without adding friction.

GLP-1 therapies are not just transforming obesity treatment, they are sending ripple effects across device categories, procedure volumes, and investment assumptions. This panel examines how MedTech companies are rethinking product strategy, pipeline priorities, and commercial models in response to a pharmacological shift that few anticipated at this scale or speed.

The Nordic region has produced a disproportionate share of MedTech innovation relative to its size. This panel explores what drives that output, how Nordic companies navigate the transition from strong domestic ecosystems to global commercial scale, and what other markets can learn from a region that consistently punches above its weight.